102 results about "Gout" patented technology

The invention provides a probiotics plant solid beverage for treating hyperuricemia and gout. The solid beverage is prepared by mixing freeze-dried probiotics powder and plant extract with the addition of proper auxiliary materials. The solid beverage comprises the following components: the plant extract, the auxiliary materials and the probiotics, with the sum of the mass percentage of each component being 100%. The plant extract comprises celery seed powder, sophora flower bud powder and platycodon root powder. The invention has an obvious effect on lowering uric acid and relieving gout.

The present disclosure relates to uricase variant polypeptides and their multimers, as well as uricase conjugates comprising (i) a first domain comprising one of the uricase variant polypeptides conjugated to (ii) a second domain comprising a random coil polypeptide domain. Methods of using the uricase variant polypeptides and uricase conjugates to treat gout, tumor lysis syndrome, and other diseases associated with elevated uric acid levels in body fluids, including blood, are provided. Methods of recombinantly producing the uricase variant polypeptides and uricase conjugates disclosed herein are also provided.

The present application relates to the preparation and application field of biological peptide, and more particularly to a hippocampus abdominalis peptide and its application in preparation of products for reducing uric acid and resisting gout. The amino acid sequence is shown as SEQ ID NO. 1, and the present application confirms the uric acid reducing effect through in vitro xanthine oxidase (XOD) and adenosine deaminase (ADA) inhibition experiments and cell experiments; on this basis, the uric acid reducing and gout resisting activity of the peptide sequence is further verified by means of a high uric acid animal model. This achievement provides a solid theoretical support for high-value development and utilization of hippocampus abdominalis, and research and development of products for reducing uric acid and resisting gout.

The utility model relates to external hot compress equipment technical field, specifically is a kind of gout conditioning machine external hot compress equipment, including concave support frame, cotton pad A and slide rail, the concave support frame top is equipped with hot compress mouth, and the concave support frame top is equipped with seat plate;The concave support frame one side top is equipped with pull-out opening, and the slide rail between is equipped with support frame through pull-out opening, and the inner wall of support frame is evenly equipped with thermostatic electric heating tube by bolt from left to right, and the concave support frame inboard is equipped with support frame corresponding pull-out opening bottom;By the slide rail cooperation support frame sliding or return corresponding hot compress mouth bottom, by the thermostatic electric heating tube of support frame inboard constant-temperature heating, to facilitate hot compress operation, by air hole and cotton pad A be cotton fibre and have good air permeability, by seat plate in hot compress mouth top to facilitate personnel sitting posture hot compress.

This invention discloses a benzofuran compound and its application in lowering uric acid activity. Compounds 1-3 were isolated from the fermentation products of the endophytic fungus *Septoriella phragmitis*, with compound 1 being a novel compound. The fermentation products were purified using mixed solvent extraction, normal silica gel column chromatography, and high-performance liquid chromatography to obtain compounds 1-3. The inhibitory activity of compounds 1-3 on xanthine oxidase, a target related to gout symptoms, was tested. Experimental results showed that the novel compound 1 exhibited good inhibitory activity against xanthine oxidase. Molecular docking experiments also demonstrated that compound 1 had a good binding energy to the target protein. Therefore, compound 1 can be used to prepare a natural lead compound for delaying or treating diseases caused by xanthine oxidase, providing a potential therapeutic agent for hyperuricemia and gout.

The invention provides pain-relieving and stasis-dissipating powder for treating soft tissue and gout, and relates to the technical field of traditional Chinese medicines. The pain-relieving and stasis-dissipating powder for treating soft tissue and gout is prepared from cortex phellodendri, fructus gardeniae, frankincense, myrrh, radix et rhizoma rhei, radix angelicae sinensis, radix angelicae and borneol. The pain-relieving and blood stasis-dissipating powder has the effects of promoting blood circulation to remove blood stasis, relieving swelling and pain, clearing heat, eliminating dampness, removing blood stasis and promoting tissue regeneration, and has a remarkable curative effect on early fracture, soft tissue injury, gout, synovitis and the like.

The present disclosure describes topical ketorolac compositions that comprise a eutectic solvent, such as choline chloride and propylene glycol, and methods and uses thereof. The compositions of the present disclosure are capable of delivering an effective amount of ketorolac through the skin and are believed to be useful in treating inflammation and / or pain, such as gout.

The present invention discloses a compound of formula (I); specifically, the invention relates to a compound shown as a formula (I) or pharmaceutically acceptable salt, stereoisomer, prodrug, deuterated derivative or solvate, and application of the compounds in drugs for treating or preventing pain, gout, epilepsy, insomnia, anxiety disorder, depression, Parkinson's syndrome and other related diseases.

The invention relates to an NEK7 inhibitor, a pharmaceutical composition and application of the NEK7 inhibitor. The NEK7 inhibitor has a structural formula as shown in a formula (I). The compound disclosed by the invention has good NEK7 inhibitory activity, and can be used for treating or preventing a plurality of inflammatory pathological diseases (Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, multiple sclerosis, atopic dermatitis, ulcerative colitis, Crohn's disease, cancer, osteoarthritis, gout and the like) regulated by NLRP3 inflammasome.

This invention belongs to the field of traditional Chinese medicine technology, specifically relating to a traditional Chinese medicine composition, its preparation method, and its uses. By mass parts, the raw materials of the traditional Chinese medicine composition include: 20-60 parts of Acorus calamus, 30-50 parts of Citrus aurantium, 20-60 parts of Benzoin, and 40-100 parts of Catechu. The traditional Chinese medicine composition of this invention has simple and natural components, and clear efficacy. It can effectively reduce the levels of XOD, SUA, CRE, BUN, TNF-α, IL-6, D-Lac, and DAO in the serum of a mouse model of gout, and significantly reduce the renal index, demonstrating good efficacy in treating hyperuricemia and / or gout.

The application relates to application of a piezoelectric material in preparation of a medicine for treating gout, characterized in that a medicine active ingredient of the medicine comprises the piezoelectric material, the piezoelectric material is barium titanate; the application comprises the following steps: delivering the medicine to a lesion site, applying ultrasonic stimulation to the lesion site, and exciting in-vivo active species degradation of uric acid by the medicine. The piezoelectric material has good piezoelectric catalytic performance, excellent tissue penetration ability, low toxicity and high precision, active species can be controllably excited by means of ultrasonic action at the time of gout attack, uric acid can be efficiently degraded into allantoin which is good in solubility and non-toxic, symptoms can be rapidly relieved, the piezoelectric material can be long-term resident in joints, can keep stable catalytic effect in multiple cycles, and long-term treatment of gout can be realized by single injection, and a new gout treatment scheme which is more effective and more durable is provided.

An external nano liniment for gout and a preparation method thereof are provided. The external nano liniment for gout includes a cream phase and nanoparticles dispersed in the cream phase, wherein the nanoparticles are a coating structure having a water phase, an oil phase and a water phase in sequence from inside to outside, an active ingredient used for treating gout is embedded or dispersed in the water phase and / or the oil phase of the nanoparticles, and a size distribution of the nanoparticles is in a range of 1-200 nm.

The present invention relates to: a novel method for preparing a heterocyclic derivative compound of chemical formula I below; a novel intermediate compound used in the preparation method; a composition for treatment or prevention of hyperuricacidemia, gout, nephritis, chronic renal insufficiency, nephrolith, uremia, urolithiasis, or a uric acid-related disease, the composition containing the compound of chemical formula I at a dose of more than 2 mg and equal to or less than 10 mg and being orally administered once a day; and a hydrochloride 1.5 hydrate of the novel compound of chemical formula I.

This invention relates to the field of probiotics technology, specifically to a Bifidobacterium adolescentis BN18 and its postbiotics for lowering uric acid and improving gout symptoms, and their applications. The Bifidobacterium adolescentis BN18 can promote the degradation of inosine and guanosine, thereby reducing uric acid levels in the blood. The postbiotics for Bifidobacterium adolescentis BN18 are made from carefully selected raw materials such as carrots, winter melon, blueberries, apples, lemons, and fructooligosaccharides as the core components of the composition. Through deep fermentation with BN18, the resulting postbiotics not only reduce the activity of xanthine oxidase and lower uric acid levels in the blood, thus promoting uric acid reduction, but also significantly enhance their antioxidant properties, reducing inflammatory responses, lowering inflammation levels, alleviating joint pain, and improving gout symptoms.

The invention provides a benzylimidazole glutamine cyclase inhibitor as well as a preparation method and application thereof, and belongs to the field of medical chemistry. The compound as shown in the formula I is prepared, the compound has good inhibitory activity on glutamine cyclase, and the half inhibitory concentration of most compounds reaches the nanomole level; the compound has a wide application prospect in preparation of drugs for treating Alzheimer's disease, depression, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's disease, tumor, synovial membrane disease, gout, acute / chronic enteritis, rheumatoid arthritis or inflammatory diseases, and lays a material basis for research and development of related drugs.

A method of treating gout in a patient is provided. The method comprises topically applying to a gout-affected area of the patient an external nano liniment comprising a cream phase and nanoparticles dispersed in the cream phase. The nanoparticles have a coating structure comprising a water phase, an oil phase and a water phase in sequence from inside to outside. Active ingredients for treating gout are embedded or dispersed in the water phase and / or the oil phase of the nanoparticles, and a particle size distribution of the nanoparticles is in a range of 1-200 nm. The topical application reduces uric acid levels in blood, dissolves gout crystals, and relieves symptoms including joint redness, swelling, hotness, and pain while avoiding systemic side effects associated with oral administration of gout medications.

The invention provides an extract with high saikoside B2 content, a preparation method and application of the extract, and a combined medicine containing the extract, and belongs to the technical field of natural medicine preparation. The method comprises the following steps: efficiently extracting saikoside A and saikoside D in a radix bupleuri raw material by using an alkaline ethanol solution, further realizing efficient resolution of saikoside A and saikoside D by using macroporous adsorption resin, and quantitatively converting saikoside D into saikoside B2 by using a chemical method, thereby obtaining the high-content effective part of saikoside B2. The high-content effective part of saikoside B2 only contains a small amount of saikoside A except the main component saikoside B2, so that the toxicity is greatly reduced while the biological activity of the saikoside B2 is ensured. The high-content effective part of saikosaponin B2 can be used for preparing medicines for treating and preventing gout, rheumatoid arthritis, acute enteritis, skin light injury, skin inflammation and other diseases, can be independently used, and can also be combined with other medicines for use.

The invention relates to the technical field of traditional Chinese medicines, in particular to a traditional Chinese medicine composition for treating rheumatoid arthritis and gout and a preparation method thereof. By adopting the formula, the traditional Chinese medicine composition for treating rheumatoid arthritis and gout has a remarkable effect on rheumatoid arthritis and gout. According to the traditional Chinese medicine composition for treating rheumatoid arthritis and gout provided by the invention, through synergistic cooperation of the components and control of the content of the components, the effects of the components can be effectively exerted, and the antagonism among the components is reduced, so that the overall effect of the traditional Chinese medicine composition is obviously improved. The traditional Chinese medicine composition for treating rheumatoid arthritis and gout provided by the invention acts on focuses of rheumatoid arthritis and gout at least through three ways of discharging turbidity and dredging collaterals, clearing away heat and toxic materials and dispelling wind and eliminating dampness, and the overall effect is ideal and stable.

The invention discloses application of external medicinal liquor in preparation of a medicine for treating gout, relates to the technical field of traditional Chinese medicines, and solves the problems of high cost, slow effect and adverse reaction of an existing ventilation treatment method. And the external medicinal liquor comprises dragon's blood, ephedra powder, cassia twig, safflower, ligusticum wallichii, red peony root, white peony root, beautiful sweetgum fruit, caltrop, fructus forsythiae, hedyotis diffusa, radix angelicae pubescentis, notopterygium root, salvia miltiorrhiza and white spirit. The preparation method comprises the following steps: drying the traditional Chinese medicine components, crushing, and putting into a three-dimensional motion mixer to obtain uniformly mixed traditional Chinese medicine powder; adding 5-8% by mass of white spirit, uniformly stirring, and activating in a vacuum drying oven; and then putting into the rest white spirit, covering, sealing and soaking for 7 days, and filtering to remove medicine residues to obtain the external medicinal liquor. The traditional Chinese medicine composition can be applied to treatment of gout diseases, and is low in cost, high in safety and quick in effect.

The invention relates to an application of a pharmaceutical composition in preparation of a medicine for treating gout or osteoporosis, belongs to the field of pharmacy, and has an obvious effect of preventing or treating gout or osteoporosis and better safety.

The application provides a gout recurrence risk assessment method and system based on a neutrophil-to-lymphocyte ratio, comprising: data acquisition, data preprocessing, and generating gout recurrence risk assessment sample data through data standardization processing; establishing a joint model of a Cox proportional hazards regression model and a competing risk model to evaluate the correlation between the neutrophil-to-lymphocyte ratio (NLR) and gout recurrence; adding NLR as a characteristic variable of a prognosis factor of gout recurrence risk to a baseline model to construct multiple gout recurrence risk candidate prediction models; screening to obtain a target gout recurrence risk assessment model; generating an evaluation result; and visual display. The method can effectively handle the problems of incomplete and skewed distribution of clinical data, improve the quality and stability of the data, improve the accuracy of evaluation and prediction by screening out an effective target gout recurrence risk assessment model, and provide reliable auxiliary decision support for clinicians.

The present application relates to a transdermal patch containing colchicine and a preparation method and use thereof. The transdermal patch comprises a matrix layer, wherein the matrix layer comprises an active ingredient colchicine, a hot melt pressure sensitive adhesive and optionally other pharmaceutically acceptable adjuvants, wherein the content of the colchicine is 0.1% to 5%, the content of the hot melt pressure sensitive adhesive is 1.9% to 99.9%, and the content of the other pharmaceutically acceptable adjuvants is 0% to 98% based on the total weight of the matrix layer. The transdermal patch containing colchicine of the present application has no local irritation during and after application, no gastrointestinal side effects, high patient compliance, strong drug permeability, good therapeutic effect, and can be used for preventing and / or treating gout and / or pericarditis.

The application provides a gout collaterals bloodletting dynamic regulation system based on CRP feedback and syndrome typing, relates to the technical field of clinical collateral auxiliary judgment systems, and comprises the following function modules: a data acquisition module, an initial strategy generation module, a real-time data acquisition module and a dynamic adjustment module. The system can assist in realizing quantification, standardization and objectivity, significantly improves the stability and repeatability of the curative effect, improves the safety, and can shorten the treatment course.

The invention relates to the technical field of biomedicine, in particular to application of hydrated electrons or a hydrated electron preparation in preparation of products for reducing uric acid and resisting inflammation or oxidation. The hydrated electron and the preparation thereof are found to be capable of effectively reducing the uric acid level, have antioxidant and anti-inflammatory effects, have obvious improvement and treatment effects on hyperuricemia, gout and inflammation and lesion of kidneys and joints caused by hyperuricemia and gout, do not have toxic or side effects and adverse reactions on animals, and are suitable for clinical application. The compound has a good application prospect in treatment of hyperuricemia and gout, and a new treatment means is provided for hyperuricemia and gout.

This invention relates to a monoclonal antibody for treating gout and a corresponding composition thereof. The invention prepares and obtains recombinant IL-1β protein, uses this protein as an immunogen to immunize mice, and prepares and obtains an IL-1β monoclonal antibody using hybridoma technology. The antibody exhibits good specificity and affinity, and its ability to effectively inhibit IL-1β expression in a gout model has been demonstrated in gout model experiments, providing an effective drug for treating gout.

A preparation method of an external nano liniment for gout is provided. The preparation method comprises the following steps: dissolving active ingredients into a water phase and / or an oil phase; adding a part of the water phase to a stirred oil phase to obtain hydrated oil phase nanoparticles; adding the hydrated oil phase nanoparticles to a part of the stirred water phase to obtain nanoparticles; and adding a cream phase to the stirred nanoparticles to obtain the nano liniment. The nanoparticles are of a coating structure having a water phase, an oil phase and a water phase in sequence from inside to outside, active ingredients used for treating gout are embedded or dispersed in the water phase and / or the oil phase of the nanoparticles, and a size distribution of the nanoparticles is in a range of 1-200 nm.

A polymorphic form of a GLP-1R agonist compound (III), a preparation method therefor and a use thereof are provided. Compared with an amorphous form of compound (III), the polymorphic form has higher stability and better processability, and is more suitable for preparing a drug for preventing or treating diseases related to a GLP-1R target and a signaling pathway thereof, such as type 2 diabetes, prediabetes, obesity, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, kidney disease, gout, hyperhematuria, cardiovascular disease, etc.

The invention discloses a traditional Chinese medicine composition for treating joint diseases and a preparation method and application thereof, and belongs to the technical field of traditional Chinese medicines. The traditional Chinese medicine composition is prepared from the following components in parts by weight: 25 to 45 parts of radix angelicae pubescentis, 25 to 45 parts of cortex phellodendri, 20 to 40 parts of rhizoma smilacis glabrae, 20 to 40 parts of rhizoma dioscoreae septemlobae, 20 to 40 parts of rhizoma chuanxiong, 20 to 40 parts of semen coicis, 20 to 40 parts of radix cyathulae, 20 to 40 parts of herba artemisiae scopariae, 20 to 40 parts of herba lycopodii, 20 to 40 parts of rhizoma polygoni cuspidati, 20 to 40 parts of radix dipsaci, 20 to 40 parts of rhizoma atractylodis, 20 to 40 parts of semen plantaginis and 10 to 25 parts of liquorice root. The traditional Chinese medicine composition has a relatively good treatment effect on gout, rheumatic arthritis and rheumatoid arthritis, can treat both symptoms and root causes, and is relatively small in side effect and relatively small in harm to a human body.

The application provides nine biomarkers-dipeptide metabolites, which can reflect the growth rate of serum-induced monosodium urate crystals and are used for evaluating the risk of gout attack of an individual. The method provided by the application can objectively reflect the difference in the growth rate of serum-induced monosodium urate crystals and the risk of gout attack of patients in different health states without complex instruments and monitoring methods.

The present application relates to compounds of formula (A), wherein R1 is selected from formula (II) and formula (III) and R2 is selected from formula (IV), formula (V) and formula (VI), as IRAK4 inhibitors for use in methods of treating, for example, asthma and chronic obstructive pulmonary disease (COPD), cancer, inflammatory diseases and autoinflammatory / autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, myositis, Sjogren's syndrome, systemic sclerosis, gout, endometriosis, atopic dermatitis and psoriasis. Preferred compounds of the present application are, for example: N-(imidazo[l,2-b]pyridazin-3-yl)-l-cyclohexyl-2H-indazole-5-carboxamide, N-(pyrazolo[l,5-a]pyrimidin-3-yl)-l-cyclohexyl-2H-indazole-5-carboxamide, N-(imidazo[l,2-b]pyridazin-3-yl)-l-azaspiro[4.5]dec-8-yl-2H-indazole-5-carboxamide and N-(pyrazolo[l,5-a]pyrimidin-3-yl)-l-azaspiro[4.5]dec-8-yl-2H-indazole-5-carboxamide derivatives. An exemplary compound of the present application is, for example: N-(imidazo[l,2-b]pyridazin-3-yl)-6-methoxy-2-((5r,8r)-l-methyl-2-oxo-l-azaspiro[4.5]dec-8-yl)-2H-indazole-5-carboxamide (Example 1): formula (VII).